PRESS RELEASE published on 01/30/2025 at 11:03, 1 year 3 months ago Résultats préliminaires pour l’année 2024 Novacyt annonce des résultats préliminaires solides pour l'année 2024, avec une croissance du chiffre d'affaires et des progrès dans ses activités cliniques, d'instrumentation et de recherche. Mise à jour financière et perspectives prometteuses Croissance Résultats Préliminaires Perspectives Activités Cliniques Novacyt
BRIEF published on 12/10/2024 at 11:59, 1 year 5 months ago Novacyt annonce le déménagement de son siège social Diagnostic Moléculaire Déménagement D'entreprise Opérations Mondiales Siège Social De Novacyt Médecine Génomique
BRIEF published on 12/10/2024 at 11:59, 1 year 5 months ago Novacyt Announces Relocation of Corporate Headquarters Global Operations Molecular Diagnostics Corporate Relocation Novacyt Headquarters Genomic Medicine
PRESS RELEASE published on 12/10/2024 at 11:54, 1 year 5 months ago Changement de siège social Novacyt announces immediate headquarters relocation to 131 Boulevard Carnot, Le Vésinet, France, reinforcing its position as a global molecular diagnostics company Headquarters Relocation Paris London Molecular Diagnostics Novacyt
PRESS RELEASE published on 11/14/2024 at 15:34, 1 year 6 months ago Expansion du programme de réduction des coûts Novacyt annonce une consolidation des installations mondiales pour améliorer l'EBITDA. Fermeture du site Eastleigh et transfert des activités de fabrication du Canada à Manchester EBITDA Consolidation Restructuration Diagnostic Moléculaire Novacyt
PRESS RELEASE published on 11/14/2024 at 15:31, 1 year 6 months ago Further expansion of cost reduction programme Novacyt announces further expansion of cost reduction programme with proposed site consolidations expected to deliver c. £2.0m EBITDA improvement, including closure of Eastleigh site and transfer of Canada manufacturing operations to Manchester Cost Reduction EBITDA Improvement Manufacturing Operations Novacyt Site Consolidations
BRIEF published on 11/14/2024 at 15:31, 1 year 6 months ago Lancement de nouveaux tests vétérinaires par Novacyt Diagnostic Moléculaire Novacyt Tests Vétérinaires Agents Pathogènes Maladies Gastro-intestinales
BRIEF published on 11/14/2024 at 15:31, 1 year 6 months ago Novacyt launches new veterinary tests Gastrointestinal Diseases Novacyt Molecular Diagnosis Veterinary Tests Pathogens
PRESS RELEASE published on 11/14/2024 at 15:26, 1 year 6 months ago Lancement de nouveaux tests multiplexes pour animaux au London Vet Show Novacyt lance de nouveaux tests multiplexes pour maladies gastro-intestinales chez les chiens et les chats au London Vet Show, offrant des résultats rapides en moins de trois heures Chiens Novacyt Maladies Gastro-intestinales Tests Multiplexes Chats
BRIEF published on 11/01/2024 at 14:00, 1 year 6 months ago Novacyt : Mise à jour sur le contrat de liquidité et les droits de vote Contrat De Liquidité Droits De Vote INVEST SECURITIES Actions Ordinaires Novacyt
Published on 05/16/2026 at 01:15, 14 hours 33 minutes ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 15 hours 48 minutes ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 16 hours 38 minutes ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/15/2026 at 23:00, 16 hours 48 minutes ago Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency
Published on 05/15/2026 at 20:10, 19 hours 38 minutes ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 21 hours 38 minutes ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 17:33, 22 hours 15 minutes ago Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 05/15/2026 at 15:08, 1 day ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 1 day ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 1 day 5 hours ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 2 days 6 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 2 days 21 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES